Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
Executive Summary
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
You may also be interested in...
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.
A US Drug Pricing Rebellion Looms, Analyst Says
Wells Fargo analyst David Maris warned biopharma investors that the US drug market is on a long-term trajectory toward price controls, which he characterized as an under-appreciated risk for the sector, ahead of President Trump's speech on drug pricing.
US FDA's Abram Makes The Case For 180-Day Exclusivity Reform
Proposed trigger changes will discourage low-quality applications, not disincentivize patent challenges, deputy commissioner suggests at generic association's annual meeting.